Data / Drug companies / Eisai Co., Ltd.
Eisai Co., Ltd.: 12 products in the FDA NDC directory, labeler code 11071
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Eisai Co., Ltd. (labeler code 11071) lists 12 products in the FDA National Drug Code Directory. By type: 10 drugs for further processing, 2 bulk ingredients. Its main marketing category is drugs for further processing. The newest product started marketing on February 13, 2015.
The request: Watch Eisai Co., Ltd. (FDA labeler code 11071): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 11071
- Products in commercial distribution
- 12
- Packages
- 12
- Finished drugs by generic name
- 0
- Prescription products
- 0
- Over the counter products
- 0
- Controlled substance products
- Schedule III 6, Schedule IV 1
- Started marketing in the last 12 months
- 0
- Earliest marketing start
- July 23, 2010
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Drugs for further processing | 10 | 83.3% |
| Bulk ingredients | 2 | 16.7% |
Products by type
| Type | Products | Share |
|---|---|---|
| Drugs for further processing | 10 | 83.3% |
| Bulk ingredients | 2 | 16.7% |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 7 | 58.3% |
| Capsule | 2 | 16.7% |
| Powder | 2 | 16.7% |
| Tablet, film coated | 1 | 8.3% |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Lenvatinib | 11071-913 | Capsule | Drugs for further processing | February 13, 2015 |
| Lenvatinib | 11071-912 | Capsule | Drugs for further processing | February 13, 2015 |
| Perampanel | 11071-907 | Tablet | Drugs for further processing | October 22, 2012 |
| Perampanel | 11071-906 | Tablet | Drugs for further processing | October 22, 2012 |
| Perampanel | 11071-905 | Tablet | Drugs for further processing | October 22, 2012 |
| Perampanel | 11071-904 | Tablet | Drugs for further processing | October 22, 2012 |
| Perampanel | 11071-903 | Tablet | Drugs for further processing | October 22, 2012 |
| Perampanel | 11071-902 | Tablet | Drugs for further processing | October 22, 2012 |
| Lorcaserin hydrochloride hemihydrate, lorcaserin | 11071-931 | Tablet | Drugs for further processing | June 27, 2012 |
| Eribulin mesylate | 11071-892 | Powder | Bulk ingredients | November 15, 2010 |
| Eribulin mesylate | 11071-891 | Powder | Bulk ingredients | November 15, 2010 |
| Donepezil hydrochloride | 11071-871 | Tablet, film coated | Drugs for further processing | July 23, 2010 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.